Lipid Panel Testing Market Growth Trajectory Through 2024-2033

Spread the love

The Lipid Panel Testing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Lipid Panel Testing Market:

https://www.thebusinessresearchcompany.com/report/lipid-panel-testing-global-market-report

According to The Business Research Company’s Lipid Panel Testing Global Market Report 2024, The lipid panel testing market size has grown strongly in recent years. It will grow from $10.28 billion in 2023 to $11.17 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increased incidence of cardiovascular diseases, growth in awareness of preventive healthcare, government initiatives for cardiovascular health, lifestyle changes and dietary patterns, aging population and chronic diseases.

The lipid panel testing market size is expected to see strong growth in the next few years. It will grow to $15.13 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to genetic testing and personalized medicine, focus on early detection and prevention, expansion of home testing kits, focus on value-based care models, increased screening in high-risk populations. Major trends in the forecast period include point-of-care testing, integration with electronic health records, genetic lipid testing, home-based testing kits, telemedicine integration, educational initiatives for lipid management.

The increasing number of cardiovascular and diabetic diseases is expected to boost the lipid panel testing market going forward. Cardiovascular disease is a group of conditions that affect the heart and blood vessels, whereas Diabetes is a metabolic disorder that affects the body’s ability to produce insulin effectively, leading to high blood sugar levels. Lipid panel testing is an essential diagnostic tool for identifying individuals at high risk of developing cardiovascular diseases or already developed cardiovascular disease. It is also be used to monitor the effectiveness of treatment in individuals who have already developed cardiovascular or diabetes disease, allowing healthcare providers to adjust treatment plans as needed to achieve target lipid levels and reduce the risk of another ailment. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 17.9 million deaths from cardiovascular diseases. Furthermore, in 2022, according to the Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report, a US-based government agency, diabetes cases in US is increased to reach 37.3 million in 2022. Therefore, improving cardiovascular and diabetic diseases will drive the lipid panel testing market forward.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10270&type=smp

The lipid panel testing market covered in this report is segmented –

1) By Product And Services: Devices, Kits, Services

2) By Prescription Mode: Prescription-Based Testing, OTC-Based Testing

3) By Application: Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hypo-Lipoproteinamia, Tangier Disease, Atherosclerosis, Other Applications

4) By End User: Hospital, Specialty Clinics And Physician Offices, Pathology Laboratories, Diagnostic Clinics, Ambulatory Surgical Centers, Reference Laboratories, Academic And Research Institutes, Other End-Users

Product innovations are a key trend gaining popularity in the lipid panel testing market. Major companies operating in the lipid panel testing market are focused on developing innovative products to sustain their position in the market. For Instance, in October 2022, Boston Heart Diagnostics, a US-based biotechnology company released LipoMap, a panel of 33 lipid, lipoprotein, and apolipoprotein tests, with most comprehensive assessments of lipid metabolism commercially available. It uncovers treatable and reversible lipid abnormalities that cause cardiovascular disease (CVD), allowing for greater personalization of treatment and follow-up testing.

The lipid panel testing market report table of contents includes: